Drug Profile
Research programme: phosphodiesterase IV inhibitor - VIA Pharmaceuticals
Latest Information Update: 25 Apr 2011
Price :
$50
*
At a glance
- Originator VIA Pharmaceuticals
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Inflammation
Most Recent Events
- 08 Aug 2007 Preclinical trials in Cardiovascular disorders in USA (unspecified route)
- 08 Aug 2007 Preclinical trials in Inflammation in USA (unspecified route)